Hint mode is switched on Switch off

Replimune Group, ordinary share
REPL, US76029N1063

FIND, SAVE & TRACK INVESTMENTS WITH CBONDS WATCHLIST

With Cbonds Watchlist you can always stay updated on your investments to make conscious decisions!

Watchlist
You need to request access
Add a stock to WL
Choose all Reset all
Replimune Group, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

  • Issuer
  • Full borrower / issuer name
    Replimune Group, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    REPL
  • Placement
    20.07.2018
  • Lock up period
    180
  • Number of papers
    6,700,000
  • Volume of raised funds
    100.5 mln USD
  • Placement share
    21.73%
  • Final placement price
    15 USD
  • Price change since placement date
    -100%
  • By capitalization
    462.58 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    REPL
  • Placement
    13.11.2019
  • Lock up period
    180
  • Number of papers
    5,000,000
  • Volume of raised funds
    86.05 mln USD
  • Placement share
    13.62%
  • Final placement price
    17.21 USD
  • Price change since placement date
    -20.69%
  • By capitalization
    631.94 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    REPL
  • Placement
    23.10.2020
  • Lock up period
    180
  • Number of papers
    4,687,500
  • Volume of raised funds
    187.5 mln USD
  • Placement share
    10.42%
  • Final placement price
    40 USD
  • Price change since placement date
    -65.88%
  • By capitalization
    1,798.72 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    REPL
  • Placement
    12.12.2022
  • Lock up period
    180
  • Number of papers
    55,113,893
  • Volume of raised funds
    126.3 mln USD
  • Placement share
    9.75%
  • Final placement price
    23.5 USD
  • Price change since placement date
    -41.91%
  • By capitalization
    1,295.18 mln USD
Other placements of the issuer Hide

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
II q eng
III q eng
IV q eng
Show all Hide

Related Stock indices

Indicators

News

07/08/2026 Replimune Group Inc. (NASDAQ: REPL) Soars on Landmark FDA Approval for Skin Cancer Drug Tudriqev
31/07/2026 Replimune Group (NASDAQ: REPL) Soars on Citigroup Upgrade and Positive FDA Panel Vote for Melanoma Drug
30/07/2026 Replimune Group: And In The Accompanying Exhibit 99.1 Shall Not Be Incorporated By Reference Into Any Filing Of The Company, Whether Made Before Or After The Date Hereof, Regardless Of Any General Incorporation Language In Such Filing, Unless Expressly Incorporated By Specific Reference To Such Filing. The Information In This Item 7.01 And The Accompanying Exhibit 99.1 Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended, Or Otherwise Subject To The Liabilities Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended, Financial Statements And Exhibits
29/07/2026 Market Downturn: Replimune Group, Inc. (NASDAQ: REPL) Leads Stock Declines Amid Regulatory Setbacks and Earnings Misses
03/02/2026 Replimune Group: Of This Current Report On Form 8k, Including Exhibit 99.1, Shall Not Be Deemed “filed” For The Purposes Of Section 18 Of Thesecurities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liabilities Of That Section, Nor Shall It Be Deemed Incorporated By Reference In Any Filing Under Thesecurities Act Of 1933, As Amended, Or Theexchange Act, Except As Expressly Stated By Specific Reference In Such Filing, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.